A strategic investor has signed a memorandum of understanding (MoU) to amass Israeli firm BioProtect, which has developed an implant to guard wholesome tissue from radiation harm, for about $200 million in money. Almeda Ventures (TASE: AMDA), a restricted partnership in healthcare investments, which owns 4% of BioProtect, has notified the Tel Aviv Inventory Change (TASE) in regards to the signing of the MoU.
Almeda will report income of about $10-12 million from the deal and a capital acquire of about $8 million. Following the announcement, Almeda’s share value rose 20% yesterday, giving a market cap of NIS 37 million. Almeda not too long ago made a smaller sale of $1.4 million for Clanz Applied sciences.
A easy however subtle thought
BioProtect was based in 2004 by Prof. Avi Domb of the Hebrew College of Jerusalem, right now the Chief Scientist of the Ministry of Science, and Dr. Adrian Paz and Shaul Shohat, each serial entrepreneurs within the area of medical units. The corporate has raised about $36 million up to now, from traders together with MVM Companions, Korea’s KBI Fund, Peregrine Ventures, TriVentures and Vincent Tchenguiz’s CBG Group.
The entrepreneurs had a easy however subtle thought: a small balloon that inflates and degrades contained in the physique would separate prostate tissue from different wholesome tissue throughout radiation remedy to deal with prostate tumors, thus defending wholesome tissue from radiation.
Since then, the corporate has already spawned a spin-off known as OrthoSpace, which makes use of the identical know-how to alleviate tissue friction to scale back ache for the orthopedic market, and in 2019 the subsidiary was offered to orthopedics company Stryker for $110 million instantly and potential for a deal of as much as $220 million tied to milestone achievements.
In the meantime, mum or dad firm BioProtect continued to develop its product. About two years after the acquisition, OrthoSpace CEO Itay Barnea, who led the sale, left Stryker and was appointed BioProtect CEO, with the purpose of selling the corporate in the identical means. Solely in 2020, after the sale of OrthoSpace, did it increase enough funds to conduct a medical trial at numerous medical facilities to show the product’s effectiveness and procure FDA approval, which was obtained on the finish of 2023. Since then, the product’s effectiveness has been demonstrated in an extra trial.
BioProtect has extra merchandise in growth, to be used in tissue safety in different forms of interventional oncology remedies in addition to in aesthetic and basic surgical procedures.
Printed by Globes, Israel enterprise information – en.globes.co.il – on January 28, 2026.
© Copyright of Globes Writer Itonut (1983) Ltd., 2026.
